IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway
The current study has, for the first time, identified IGFBP2 as a novel protector against hepatosteatosis. The protective effect is mediated by its specific interaction with EGFR and thereby suppressing the EGFR-STAT3 pathway. Therefore, pharmaceutically targeting the IGFBP2-EGFR-STAT3 axis may provide a theoretical basis for for the treatment of NAFLD/NASH and the associated diseases.
Authors
- Tianyu Zhai (ORCID: https://orcid.org/0000-0002-8899-4710)
- Mingfeng Xia (ORCID: https://orcid.org/0000-0002-5650-0165)
- Chenling Pan (ORCID: https://orcid.org/0000-0001-8510-9344)
- Liang Cai (ORCID: https://orcid.org/0000-0002-0746-4284)
- Pu Xia (ORCID: https://orcid.org/0000-0003-4705-8878)
- Hua Bian (ORCID: https://orcid.org/0000-0001-8449-0665)
- Xin Gao (ORCID: https://orcid.org/0000-0003-1864-7796)
- Xi Jia
Institutions
- Fudan University (CN)
- Institute of Computing Technology (CN)
- Zhongshan Hospital (CN)
- Beijing Computing Center (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.molmet.2024.102026
- Citations
- 7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- National Natural Science Foundation of China
- Fudan University
- Zhongshan Hospital